Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

P

Progen Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Age Related Macular Degeneration

Treatments

Drug: CGC-11047

Study type

Interventional

Funder types

Industry

Identifiers

NCT00446654
47-MD-002

Details and patient eligibility

About

The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.

Full description

The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals. Half of the participants in the study will receive CGC-11047 every two weeks and half of the participants in the study will receive CGC-11047 every four weeks. If your doctor determines that you are eligible for the study based on his/her judgement and according to the entry requirements set by the sponsor of the research, you will be randomly assigned (by chance, like the flip of a coin), to receive CGC-11047 every two weeks or every four weeks. Whether you receive drug every two weeks or every four weeks, you will still need to come to the clinic approximately every two weeks for the first three months, and approximately four times after that until it has been at least 12 months since you received your first treatment of study drug. Two studies (this one and another one) are occurring to test CGC-11047 in patients with wet age-related macular degeneration for the first time. However, this drug (CGC-11047) is being studied in cancer patients at doses much higher than will be given to any subjects in either of these studies. The cancer patients have tolerated the drug well with the exception of one cancer patient who had two reactions to the drug (pancreatitis and hypotension). However, this patient had advanced cancer (non-Hodgkin's lymphoma with a life expectancy of less than 3 months) and received 38X the dose to be administered in this AMD study. Aside from this one patient, there have not been any serious side effects related to the drug. This study will involve about 100 subjects at about 15 different sites internationally. The study will take place over 12 months and will include about 12 office visits to the study doctor.

Enrollment

43 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a diagnosis of subfoveal choroidal neovascularization secondary to AMD in the study eye, with leaking present on a fluorescein angiogram as determined by the clinical investigator.
  • Visual acuity: BCVA in the study eye between 20/40 and 20/320 and better than or equal to 20/320 in the fellow eye.
  • Patients who refuse standard of care or have not benefited from standard of care in the opinion of the principal investigator.
  • Clear ocular media and adequate pupillary dilatation to permit good quality ophthalmologic exam.
  • Male or female patients aged >= 50 years.
  • Ability to understand and the willingness to sign a written informed consent document and return for all study visits.

Exclusion criteria

  • Patients with CNV not due to AMD in the study eye.
  • Patients with a retinal tear in the study eye.
  • Patient has a subretinal hemorrhage that comprises more than 50% of total lesion size, or has atrophy or fibrosis in the center of fovea.
  • Patients who have undergone intraocular surgery within 2 months or extrafoveal/juxtafoveal laser within 3 months of study entry in the study eye.
  • Any macular disease other than AMD causing vision loss in either eye.
  • Active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye. Anterior segment diseases such as blepharitis, ocular rosacea, lid problems which could increase the risk of infection after study drug injection.
  • Uncontrolled glaucoma (defined as intraocular pressure >25 mmHg (P0) on maximum medical therapy) or clinically significant glaucomatous visual field loss in both eyes.
  • Significant media opacities, including cataract that might interfere with visual acuity, assessment of toxicities or fundus photography in the study eye in the judgement of the clinical investigator.
  • Spherical refractive error more than -8.0 diopters in the study eye.
  • Use of any approved or investigational AMD agent (standard of care) within four weeks of study enrollment.
  • Use of any systemic investigational agent within 30 days of study enrollment.
  • Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with a clinically significant or symptomatic cardiac arrhythmia, recent myocardial infarction (within 6 months), or evidence of a current significant ventricular conduction abnormality.
  • Women who are pregnant or breast-feeding.
  • Women of childbearing potential and male patients who are partners of women of childbearing potential who are unwilling to use approved, effective means of contraception according to the institution's standards.
  • Allergy to fluorescein dye.

Trial design

43 participants in 2 patient groups

CGC-11047 once every 2 weeks
Experimental group
Description:
16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
Treatment:
Drug: CGC-11047
CGC-11047 once every four weeks
Experimental group
Description:
16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
Treatment:
Drug: CGC-11047

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems